Drug containment and delivery solutions provider SCHOTT Pharma has announced an investment of more than €100m ($114m) to expand its manufacturing capacity for sterile ready-to-use (RTU) cartridges at its site in Lukácsháza, Hungary.
The new facility will create 100 jobs.
Go deeper with GlobalData
RTU cartridges are essential for storing glucagon-like peptide-1 drugs, biologics, insulin and hormone therapies used for treating diabetes, obesity and other immunological conditions.
It will further extend the site’s manufacturing capabilities for high-value solutions.
SCHOTT Pharma plans to implement a fully integrated and automated production process with minimal manual intervention, ensuring the delivery of sterile products.
The facility will also feature a new washing line and a steam sterilisation process for cartridges, aimed at decreasing the environmental impact of the operations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSCHOTT Pharma CEO Andreas Reisse stated: “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields. That is why we are investing more than €100m in our plant in Hungary.”
In June 2024, the company opened a new facility at the same site, which has already begun producing high-quality prefillable glass syringes.
With an additional 120 employees, the site has increased its production capacity to meet the growing demand for these critical components in the healthcare industry.
Lukácsháza site manager Eva Szabó stated: “We would like to express our sincerest gratitude to the Ministry of Foreign Affairs and Trade for its support of these two expansion projects.
“Lukácsháza is not only an important location for ensuring supply security to customers in the region but also makes an important contribution to SCHOTT Pharma’s global growth strategy.”
Lukácsháza will become the second SCHOTT Pharma site, after St Gallen in Switzerland, for sterile cartridge manufacturing.
The company’s portfolio includes a variety of delivery systems and drug containment solutions for injectable drugs, such as prefillable glass and polymer syringes, cartridges, ampoules and vials.
